SG10202101105XA - Charged depth filtration of antigen-binding proteins - Google Patents

Charged depth filtration of antigen-binding proteins

Info

Publication number
SG10202101105XA
SG10202101105XA SG10202101105XA SG10202101105XA SG10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA SG 10202101105X A SG10202101105X A SG 10202101105XA
Authority
SG
Singapore
Prior art keywords
antigen
binding proteins
depth filtration
charged depth
charged
Prior art date
Application number
SG10202101105XA
Inventor
Hai Hoang
Rafael Gonzalez
Junfen Ma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202101105X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG10202101105XA publication Critical patent/SG10202101105XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10202101105XA 2015-08-13 2016-08-12 Charged depth filtration of antigen-binding proteins SG10202101105XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562204831P 2015-08-13 2015-08-13

Publications (1)

Publication Number Publication Date
SG10202101105XA true SG10202101105XA (en) 2021-03-30

Family

ID=56802689

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202101105XA SG10202101105XA (en) 2015-08-13 2016-08-12 Charged depth filtration of antigen-binding proteins

Country Status (15)

Country Link
US (2) US11098079B2 (en)
EP (2) EP3334747B1 (en)
JP (1) JP6889149B2 (en)
DK (1) DK3334747T3 (en)
ES (1) ES2964640T3 (en)
FI (1) FI3334747T3 (en)
HR (1) HRP20231544T1 (en)
HU (1) HUE064252T2 (en)
LT (1) LT3334747T (en)
MA (1) MA42613A (en)
PL (1) PL3334747T3 (en)
PT (1) PT3334747T (en)
SG (1) SG10202101105XA (en)
SI (1) SI3334747T1 (en)
WO (1) WO2017027861A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN107973487B (en) * 2017-11-14 2021-03-02 东华大学 Dyeing and finishing wastewater hierarchical treatment process and device
KR102503349B1 (en) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 Methods and compositions for preventing type 1 diabetes
EP4090666A1 (en) * 2020-01-15 2022-11-23 F. Hoffmann-La Roche AG Methods to decrease impurities from recombinant protein manufacturing processes
CN111410688A (en) * 2020-03-13 2020-07-14 苏州智享众创孵化管理有限公司 Separation and purification method for improving purity of bispecific antibody

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (en) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc Monoclonal antibody-containing lyophilized preparation
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE4344824C1 (en) 1993-12-28 1995-08-31 Immuno Ag Highly concentrated immunoglobulin preparation and process for its preparation
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EA010435B1 (en) 2001-05-11 2008-08-29 Амген, Инк. Binding to tall-1 molecules and use thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
KR20040023630A (en) 2001-06-26 2004-03-18 아브게닉스, 인크. Antibodies to opgl
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
BR0212136A (en) 2001-08-23 2004-12-07 Genmab As Isolated human monoclonal antibody, methods for inhibiting tnfa production in t cells or monocytes and t cell proliferation, hybridoma, transfectoma, transgenic non-human animal, method for producing a human monoclonal antibody, pharmaceutical composition, methods for treating or preventing a human il-15 mediated disorder, psoriasis and rheumatoid arthritis, method for diagnosing a disease, nucleic acid, and expression vector
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
KR100913714B1 (en) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Stable liquid pharmaceutical formulation of igg antibodies
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
TWI347951B (en) 2002-09-06 2011-09-01 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
PL216630B1 (en) 2002-10-17 2014-04-30 Genmab As Human monoclonal antibodies against cd20
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
MEP57508A (en) 2002-12-20 2011-05-10 Amgen Inc Binding agents which inhibit myostatin
PL2335725T3 (en) 2003-04-04 2017-04-28 Genentech, Inc. High concentration antibody and protein formulations
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
ME02785B (en) 2003-07-15 2012-12-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
PL1682178T3 (en) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Methods of therapy for cancers expressing the cd40 antigen
UA93653C2 (en) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Antibody that specifically binds to human interleukin-4 receptor (il-4r)
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
WO2007035283A1 (en) 2005-09-15 2007-03-29 Wyeth Protein floculation using salts
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
WO2008051448A2 (en) * 2006-10-19 2008-05-02 Tolerx, Inc. Methods and compositions for efficient removal of protein a from binding molecule preparations
PL3327026T3 (en) 2007-07-09 2020-02-28 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008037678A1 (en) * 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Depth filter layer with inorganic layer double hydroxide
JP5808249B2 (en) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド Antibody isolation and purification using protein A affinity chromatography
PL2424889T3 (en) * 2009-04-30 2016-01-29 Ablynx Nv Method for the production of domain antibodies
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
CA2775595A1 (en) 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011140405A1 (en) * 2010-05-07 2011-11-10 Millipore Corporation Enhanced clarification media
MX354845B (en) 2010-05-18 2018-03-22 Abbvie Inc Star APPARATUS and PROCESS OF PURIFICATION OF PROTEINS.
SG189872A1 (en) 2010-10-11 2013-06-28 Abbvie Inc Processes for purification of proteins
AU2011317021B2 (en) * 2010-10-20 2015-07-09 Medimmune, Llc Methods for processing inclusion bodies
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
KR102157227B1 (en) 2011-07-08 2020-09-17 이엠디 밀리포어 코포레이션 Improved depth filters for disposable biotechnological processes
FR2977893B1 (en) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement PROCESS FOR PREPARING A CONCENTRATE OF MULTIPURPOSE IMMUNOGLOBULINS
DK2739641T4 (en) 2011-08-02 2020-06-15 Baxalta GmbH SYSTEMS AND PROCEDURES TO INCREASE PROTEIN EXPENDITURE FROM RECOMMINATED PROCEDURES
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
KR20200008022A (en) 2011-12-22 2020-01-22 제넨테크, 인크. Ion exchange membrane chromatography
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013177118A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of non-human antibodies using protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
JP6553515B2 (en) * 2012-12-20 2019-07-31 メディミューン，エルエルシー Method for producing immune complex
JP2016520655A (en) 2013-06-04 2016-07-14 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Protein purification process
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201318840D0 (en) 2013-10-24 2013-12-11 Univ Leeds Method and device for protein preparation
US20160272673A1 (en) * 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of dvd-igs
JP2017507149A (en) 2014-02-27 2017-03-16 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Antibody purification method
US20170191101A1 (en) 2014-03-17 2017-07-06 Regeneron Pharmaceuticals, Inc. Clarification of mammalian cell culture
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins

Also Published As

Publication number Publication date
DK3334747T3 (en) 2023-12-11
ES2964640T3 (en) 2024-04-08
JP2018526357A (en) 2018-09-13
US11098079B2 (en) 2021-08-24
EP3334747B1 (en) 2023-09-27
US20180230180A1 (en) 2018-08-16
US20210363180A1 (en) 2021-11-25
FI3334747T3 (en) 2023-11-30
MA42613A (en) 2018-06-20
PL3334747T3 (en) 2024-04-02
HRP20231544T1 (en) 2024-03-15
JP6889149B2 (en) 2021-06-18
HUE064252T2 (en) 2024-02-28
LT3334747T (en) 2023-12-27
WO2017027861A1 (en) 2017-02-16
PT3334747T (en) 2023-12-12
EP4209499A1 (en) 2023-07-12
SI3334747T1 (en) 2024-02-29
EP3334747A1 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
IL285366A (en) Multispecific antigen-binding proteins
HK1253235A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL263690A (en) Purification of multispecific antibodies
HK1231400A1 (en) Selective reduction of proteins
IL251125B (en) Methods of separating gemcitabine-phosphate diastereoisomers
SG10202101105XA (en) Charged depth filtration of antigen-binding proteins
IL248697A0 (en) Methods of purifying antibodies
ZA201808524B (en) Methods of affecting separation
GB201604627D0 (en) Improved method of FT-IMS
IL272670A (en) Preparation of micro-electrodes
SG10202007893TA (en) Methods of immunotherapy
IL252712A0 (en) Method of protein manufacture
IL248694A0 (en) Nanoencapsulation of antigen-binding molecules
HK1223624A1 (en) Solid forms of tenofovir
GB201609314D0 (en) Methods of forming compounds
TWM533475U (en) Improved structure of filter
GB201508443D0 (en) Methods of identifying USP-binding compounds